Bench to bedside and back again: Molecular mechanisms of α-catenin function and roles in tumorigenesis

Seminars in Cancer Biology

Volumn 18, Issue 1, 2008, Pages 53-64

  Benjamin, Jacqueline M ^a   Nelson, W James ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Catenin; Adhesion; Cancer; Cytoskeleton; E cadherin

Indexed keywords

ACTIN; ACTIN RELATED PROTEIN 2-3 COMPLEX; ALPHA CATENIN; GROWTH FACTOR; UVOMORULIN; WNT PROTEIN;

CARCINOGENESIS; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSKELETON; DESMOSOME; GAP JUNCTION; HUMAN; HUMAN CELL; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ACTINS; ALPHA CATENIN; ANIMALS; APOPTOSIS; BETA CATENIN; CADHERINS; CELL ADHESION; CELL POLARITY; CELL PROLIFERATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROFILAMENTS; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 37249054451     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2007.08.003     Document Type: Review

References (204)

1. Aijaz S., Balda M.S., and Matter K. Tight junctions: molecular architecture and function. Int Rev Cytol 248 (2006) 261-298
2. Kottke M.D., Delva E., and Kowalczyk A.P. The desmosome: cell science lessons from human diseases. J Cell Sci 119 Pt 5 (2006) 797-806
3. Perez-Moreno M., Jamora C., and Fuchs E. Sticky business: orchestrating cellular signals at adherens junctions. Cell 112 4 (2003) 535-548
4. Vestweber D., and Kemler R. Identification of a putative cell adhesion domain of uvomorulin. EMBO J 4 13A (1985) 3393-3398
5. Larue L., et al. E-cadherin null mutant embryos fail to form a trophectoderm epithelium. Proc Natl Acad Sci USA 91 17 (1994) 8263-8267
6. Torres M., et al. An alpha-E-catenin gene trap mutation defines its function in preimplantation development. Proc Natl Acad Sci USA 94 3 (1997) 901-906
7. Avizienyte E., and Frame M.C. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol 17 5 (2005) 542-547
8. Thiery J.P., and Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7 2 (2006) 131-142
9. Boggon T.J., et al. C-cadherin ectodomain structure and implications for cell adhesion mechanisms. Science 296 5571 (2002) 1308-1313
10. Haussinger D., et al. Proteolytic E-cadherin activation followed by solution NMR and X-ray crystallography. EMBO J 23 8 (2004) 1699-1708
11. Chen Y.T., Stewart D.B., and Nelson W.J. Coupling assembly of the E-cadherin/beta-catenin complex to efficient endoplasmic reticulum exit and basal-lateral membrane targeting of E-cadherin in polarized MDCK cells. J Cell Biol 144 4 (1999) 687-699
12. Hinck L., et al. Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol 125 6 (1994) 1327-1340
13. Huber A.H., et al. The cadherin cytoplasmic domain is unstructured in the absence of beta-catenin. A possible mechanism for regulating cadherin turnover. J Biol Chem 276 15 (2001) 12301-12309
14. Aberle H., et al. Assembly of the cadherin-catenin complex in vitro with recombinant proteins. J Cell Sci 107 Pt 12 (1994) 3655-3663
15. Rimm D.L., et al. Alpha 1 (E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Proc Natl Acad Sci USA 92 19 (1995) 8813-8817
16. Davis M.A., Ireton R.C., and Reynolds A.B. A core function for p120-catenin in cadherin turnover. J Cell Biol 163 3 (2003) 525-534
17. Lilien J., and Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin. Curr Opin Cell Biol 17 5 (2005) 459-465
18. Sallee J.L., Wittchen E.S., and Burridge K. Regulation of Cell Adhesion by Protein-tyrosine Phosphatases: II. Cell-cell adhesion. J Biol Chem 281 24 (2006) 16189-16192
19. Piedra J., et al. p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction. Mol Cell Biol 23 7 (2003) 2287-2297
20. Hajra K.M., and Fearon E.R. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 34 3 (2002) 255-268
21. Huber M.A., Kraut N., and Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17 5 (2005) 548-558
22. Cavallaro U., and Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4 2 (2004) 118-132
23. Chambers A.F., Groom A.C., and MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2 8 (2002) 563-572
24. Cancer Facts and Figures 2007. Atlanta: American Cancer Society.
25. Sobin L.H. Cancer staging: future directions for the TNM classification. Semin Surg Oncol 8 2 (1992) 107-110
26. Cross S.S. Grading and scoring in histopathology. Histopathology 33 2 (1998) 99-106
27. Reynolds A.B., and Roczniak-Ferguson A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene 23 48 (2004) 7947-7956
28. Nelson W.J., and Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303 5663 (2004) 1483-1487
29. Vestweber D., and Kemler R. Rabbit antiserum against a purified surface glycoprotein decompacts mouse preimplantation embryos and reacts with specific adult tissues. Exp Cell Res 152 1 (1984) 169-178
30. Vestweber D., and Kemler R. Some structural and functional aspects of the cell adhesion molecule uvomorulin. Cell Differ 15 2-4 (1984) 269-273
31. 2+-dependent cell adhesion molecule. Bioessays 11 4 (1989) 88-91
32. Shimoyama Y., et al. Cadherin dysfunction in a human cancer cell line: possible involvement of loss of alpha-catenin expression in reduced cell-cell adhesiveness. Cancer Res 52 20 (1992) 5770-5774
33. Desmond J.C., et al. Discovery of epigenetically silenced genes in acute myeloid leukemias. Leukemia 21 5 (2007) 1026-1034
34. Ulger C., et al. Comprehensive genome-wide comparison of DNA and RNA level scan using microarray technology for identification of candidate cancer-related genes in the HL-60 cell line. Cancer Genet Cytogenet 147 1 (2003) 28-35
35. Vermeulen S.J., et al. Transition from the noninvasive to the invasive phenotype and loss of alpha-catenin in human colon cancer cells. Cancer Res 55 20 (1995) 4722-4728
36. Morton R.A., et al. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells. Cancer Res 53 15 (1993) 3585-3590
37. Liu T.X., et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 13 1 (2007) 78-83
38. Tuhkanen H., et al. Marked allelic imbalance on chromosome 5q31 does not explain alpha-catenin expression in epithelial ovarian cancer. Gynecol Oncol 94 2 (2004) 416-421
39. Breen E., et al. Poorly differentiated colon carcinoma cell lines deficient in alpha-catenin expression express high levels of surface E-cadherin but lack Ca (2+)-dependent cell-cell adhesion. Cell Adhes Commun 1 3 (1993) 239-250
40. Kim Y.T., et al. Expression of E-cadherin and alpha-, beta-, gamma-catenin proteins in endometrial carcinoma. Yonsei Med J 43 6 (2002) 701-711
41. Scholten A.N., et al. Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int J Gynecol Cancer 16 3 (2006) 1379-1385
42. Setoyama T., et al. alpha-catenin is a significant prognostic factor than E-cadherin in esophageal squamous cell carcinoma. J Surg Oncol 95 2 (2007) 148-155
43. Matsui S., et al. Immunohistochemical evaluation of alpha-catenin expression in human gastric cancer. Virchows Arch 424 4 (1994) 375-381
44. Mialhe A., et al. Expression of E-cadherin and alpha-, beta- and gamma-catenins in human bladder carcinomas: are they good prognostic factors?. Invasion Metastasis 17 3 (1997) 124-137
45. Kadowaki T., et al. E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res 54 1 (1994) 291-296
46. Gofuku J., et al. Expression of E-cadherin and alpha-catenin in patients with colorectal carcinoma. Correlation with cancer invasion and metastasis. Am J Clin Pathol 111 1 (1999) 29-37
47. Nakopoulou L., et al. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology 40 6 (2002) 536-546
48. Nakanishi Y., et al. Expression of E-cadherin, alpha-catenin, beta-catenin and plakoglobin in esophageal carcinomas and its prognostic significance: immunohistochemical analysis of 96 lesions. Oncology 54 2 (1997) 158-165
49. Kimura K., et al. Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 16 6 (2000) 1125-1131
50. Shimazui T., et al. Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. Int J Cancer 74 5 (1997) 523-528
51. Hashizume R., et al. Expression of beta-catenin in normal breast tissue and breast carcinoma: a comparative study with epithelial cadherin and alpha-catenin. Histopathology 29 2 (1996) 139-146
52. Xiangming C., et al. Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology 57 2 (1999) 131-137
53. Vasioukhin V., et al. Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. Cell 104 4 (2001) 605-617
54. Drees F., et al. Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell 123 5 (2005) 903-915
55. Yamada S., et al. Deconstructing the cadherin-catenin-actin complex. Cell 123 5 (2005) 889-901
56. Pokutta S., and Weis W.I. Structure of the dimerization and beta-catenin-binding region of alpha-catenin. Mol Cell 5 3 (2000) 533-543
57. Pollard T.D., and Borisy G.G. Cellular motility driven by assembly and disassembly of actin filaments. Cell 112 4 (2003) 453-465
58. Weis W.I., and Nelson W.J. Re-solving the cadherin-catenin-actin conundrum. J Biol Chem 281 47 (2006) 35593-35597
59. Hirvikoski P., et al. Cytoplasmic accumulation of alpha-catenin is associated with aggressive features in laryngeal squamous-cell carcinoma. Int J Cancer 79 5 (1998) 546-550
60. Baloch Z.W., Pasha T., and LiVolsi V.A. Cytoplasmic accumulation of alpha-catenin in thyroid neoplasms. Head Neck 23 7 (2001) 573-578
61. Ropponen K.M., et al. Reduced expression of alpha catenin is associated with poor prognosis in colorectal carcinoma. J Clin Pathol 52 1 (1999) 10-16
62. Aaltomaa S., et al. Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer. Br J Cancer 80 3-4 (1999) 477-482
63. Burks J., and Agazie Y.M. Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3. Oncogene 25 54 (2006) 7166-7179
64. Mohi M.G., and Neel B.G. The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev 17 1 (2007) 23-30
65. Beausoleil S.A., et al. Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci USA 101 33 (2004) 12130-12135
66. Collins M.O., et al. Proteomic analysis of in vivo phosphorylated synaptic proteins. J Biol Chem 280 7 (2005) 5972-5982
67. Briggs M.W., and Sacks D.B. IQGAP proteins are integral components of cytoskeletal regulation. EMBO Rep 4 6 (2003) 571-574
68. Kuroda S., et al. Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin- mediated cell-cell adhesion. Science 281 5378 (1998) 832-835
69. Mataraza J.M., et al. IQGAP1 promotes cell motility and invasion. J Biol Chem 278 42 (2003) 41237-41245
70. Dong P., et al. Overexpression and diffuse expression pattern of IQGAP1 at invasion fronts are independent prognostic parameters in ovarian carcinomas. Cancer Lett 243 1 (2006) 120-127
71. McDonald K.L., et al. IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol 66 5 (2007) 405-417
72. Nakamura H., et al. Expression pattern of the scaffold protein IQGAP1 in lung cancer. Oncol Rep 13 3 (2005) 427-431
73. Nabeshima K., et al. Immunohistochemical analysis of IQGAP1 expression in human colorectal carcinomas: its overexpression in carcinomas and association with invasion fronts. Cancer Lett 176 1 (2002) 101-109
74. Miyamoto S., et al. Changes in E-cadherin associated with cytoplasmic molecules in well and poorly differentiated endometrial cancer. Br J Cancer 83 9 (2000) 1168-1175
75. Takemoto H., et al. Localization of IQGAP1 is inversely correlated with intercellular adhesion mediated by e-cadherin in gastric cancers. Int J Cancer 91 6 (2001) 783-788
76. Sugimoto N., et al. IQGAP1, a negative regulator of cell-cell adhesion, is upregulated by gene amplification at 15q26 in gastric cancer cell lines HSC39 and 40A. J Hum Genet 46 1 (2001) 21-25
77. Shimao Y., et al. Complex formation of IQGAP1 with E-cadherin/catenin during cohort migration of carcinoma cells. Its possible association with localized release from cell-cell adhesion. Virchows Arch 441 2 (2002) 124-132
78. Bensenor L.B., et al. IQGAP1 regulates cell motility by linking growth factor signaling to actin assembly. J Cell Sci 120 Pt 4 (2007) 658-669
79. Steffen A., et al. Filopodia formation in the absence of functional WAVE- and Arp2/3-complexes. Mol Biol Cell 17 6 (2006) 2581-2591
80. Iwaya K., Norio K., and Mukai K. Coexpression of Arp2 and WAVE2 predicts poor outcome in invasive breast carcinoma. Mod Pathol 20 3 (2007) 339-343
81. Evans W.H., De Vuyst E., and Leybaert L. The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem J 397 1 (2006) 1-14
82. King T.J., and Bertram J.S. Connexins as targets for cancer chemoprevention and chemotherapy. Biochim Biophys Acta 1719 1-2 (2005) 146-160
83. Mehta P.P., et al. Suppression of human prostate cancer cell growth by forced expression of connexin genes. Dev Genet 24 1-2 (1999) 91-110
84. Govindarajan R., et al. Impaired trafficking of connexins in androgen-independent human prostate cancer cell lines and its mitigation by alpha-catenin. J Biol Chem 277 51 (2002) 50087-50097
85. Taniguchi T., et al. Identification of regions of alpha-catenin required for desmosome organization in epithelial cells. Int J Mol Med 16 6 (2005) 1003-1008
86. Bukholm I.K., Nesland J.M., and Borresen-Dale A.L. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [see comments]. J Pathol 190 1 (2000) 15-19
87. Ikeguchi M., Makino M., and Kaibara N. Clinical significance of E-cadherin-catenin complex expression in metastatic foci of colorectal carcinoma. J Surg Oncol 77 3 (2001) 201-207
88. Ilyas M. Adhesion molecule expression in breast cancer: the phoenix in tumour metastasis?. J Pathol 190 1 (2000) 3-5
89. Watabe M., et al. Induction of polarized cell-cell association and retardation of growth by activation of the E-cadherin-catenin adhesion system in a dispersed carcinoma line. J Cell Biol 127 1 (1994) 247-256
90. Lien W.H., et al. alphaE-catenin controls cerebral cortical size by regulating the hedgehog signaling pathway. Science 311 5767 (2006) 1609-1612
91. Molina J.R., and Adjei A.A. The Ras/Raf/MAPK pathway. J Thorac Oncol 1 1 (2006) 7-9
92. Adjei A.A. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93 14 (2001.) 1062-1074
93. Schmidt C.R., et al. Dysregulation of E-cadherin by oncogenic Ras in intestinal epithelial cells is blocked by inhibiting MAP kinase. Am J Surg 186 5 (2003) 426-430
94. Schmidt C.R., et al. E-cadherin is regulated by the transcriptional repressor SLUG during Ras-mediated transformation of intestinal epithelial cells. Surgery 138 2 (2005) 306-312
95. Nam J.S., et al. Ras farnesylation inhibitor FTI-277 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Jpn J Cancer Res 93 9 (2002) 1020-1028
96. Kobielak A., and Fuchs E. Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin. Proc Natl Acad Sci USA 103 7 (2006) 2322-2327
97. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 441 7092 (2006) 431-436
98. Evangelista M., Tian H., and de Sauvage F.J. The hedgehog signaling pathway in cancer. Clin Cancer Res 12 20 Pt 1 (2006) 5924-5928
99. Perez-Moreno M., and Fuchs E. Catenins: keeping cells from getting their signals crossed. Dev Cell 11 5 (2006) 601-612
100. Strano S., et al. Mutant p53: an oncogenic transcription factor. Oncogene 26 15 (2007) 2212-2219
101. Nozawa N., et al. Immunohistochemical alpha- and beta-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma. Pathol Res Pract 202 9 (2006) 639-650
102. Nemade R.V., et al. Biogenesis and function of mouse mammary epithelium depends on the presence of functional alpha-catenin. Mech Dev 121 1 (2004) 91-99
103. Giannini A.L., Vivanco M., and Kypta R.M. alpha-catenin inhibits beta-catenin signaling by preventing formation of a beta-catenin*T-cell factor*DNA complex. J Biol Chem 275 29 (2000) 21883-21888
104. Merdek K.D., Nguyen N.T., and Toksoz D. Distinct activities of the alpha-catenin family, alpha-catulin and alpha-catenin, on beta-catenin-mediated signaling. Mol Cell Biol 24 6 (2004) 2410-2422
105. Hwang S.G., et al. Regulation of beta-catenin signaling and maintenance of chondrocyte differentiation by ubiquitin-independent proteasomal degradation of alpha-catenin. J Biol Chem 280 13 (2005) 12758-12765
106. El-Bahrawy M., et al. Variable nuclear localization of alpha-catenin in colorectal carcinoma. Lab Invest 82 9 (2002) 1167-1174
107. Bukholm I.K., et al. E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 185 3 (1998) 262-266
108. Bukholm I.R., Nesland J.M., and Bukholm G. Expression of adhesion proteins E-cadherin, alpha-catenin, beta-catenin and gamma-catenin is different in T1 and T2 breast tumours. Pathology 38 5 (2006) 403-407
109. Canavese G., et al. Expression of the E-cadherin-catenins complex in sentinel node is related to tumor morphology but not to spread to nonsentinel nodes. Pathol Res Pract 203 (2007) 517-523
110. Esposito N.N., Chivukula M., and Dabbs D.J. The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study. Mod Pathol 20 1 (2007) 130-138
111. Gillett C.E., et al. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol 193 4 (2001) 433-441
112. Gonzalez M.A., et al. An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer. J Pathol 187 5 (1999) 523-529
113. Kuroda H., et al. Expression of E-cadherin, alpha-catenin, and beta-catenin in tubulolobular carcinoma of the breast. Virchows Arch 448 4 (2006) 500-505
114. Park D., et al. Expression pattern of adhesion molecules (E-cadherin, alpha-, beta-, gamma-catenin and claudin-7), their influence on survival in primary breast carcinoma, and their corresponding axillary lymph node metastasis. Apmis 115 1 (2007) 52-65
115. Pedersen K.B., et al. Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies. Br J Cancer 87 11 (2002) 1281-1286
116. Rimm D.L., Sinard J.H., and Morrow J.S. Reduced alpha-catenin and E-cadherin expression in breast cancer. Lab Invest 72 5 (1995) 506-512
117. Robles-Frias A., et al. Robinson cytologic grading in invasive ductal carcinoma of the breast: correlation with E-cadherin and alpha-, beta- and gamma-catenin expression and regional lymph node metastasis. Acta Cytol 50 2 (2006) 151-157
118. Yoshida R., et al. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol 18 3 (2001) 513-520
119. Zschiesche W., et al. Expression of E-cadherin and catenins in invasive mammary carcinomas. Anticancer Res 17 1B (1997) 561-567
120. Anttila M., et al. Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. J Clin Oncol 16 8 (1998) 2591-2600
121. Carico E., et al. E-cadherin and alpha-catenin expression during tumor progression of cervical carcinoma. Gynecol Oncol 80 2 (2001) 156-161
122. Davidson B., et al. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol 192 4 (2000) 460-469
123. Davies B.R., Worsley S.D., and Ponder B.A. Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology 32 1 (1998) 69-80
124. Fujimoto J., et al. Expression of E-cadherin and alpha- and beta-catenin mRNAs in ovarian cancers. Cancer Lett 115 2 (1997) 207-212
125. Fujimoto J., et al. Expression of E-cadherin and alpha- and beta-catenin mRNAs in uterine cervical cancers. Tumour Biol 18 4 (1997) 206-212
126. Fujimoto J., et al. Suppression of E-cadherin and alpha- and beta-catenin mRNA expression in the metastatic lesions of gynecological cancers. Eur J Gynaecol Oncol 18 6 (1997) 484-487
127. Fujimoto J., et al. Expressions of E-cadherin and alpha- and beta-catenin mRNAs in uterine endometrial cancers. Eur J Gynaecol Oncol 19 1 (1998) 78-81
128. Marques F.R., et al. Immunohistochemical patterns for alpha- and beta-catenin, E- and N-cadherin expression in ovarian epithelial tumors. Gynecol Oncol 94 1 (2004) 16-24
129. Krishnadath K.K., et al. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol 182 3 (1997) 331-338
130. Lin Y.C., et al. Prognostic and clinicopathological features of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin and cyclin D1 expression in human esophageal squamous cell carcinoma. World J Gastroenterol 10 22 (2004) 3235-3239
131. Washington K., et al. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod Pathol 11 9 (1998) 805-813
132. Ghadimi B.M., et al. Immunohistological analysis of E-cadherin, alpha-, beta- and gamma-catenin expression in colorectal cancer: implications for cell adhesion and signaling. Eur J Cancer 35 1 (1999) 60-65
133. Hao X., et al. Reduced expression of molecules of the cadherin/catenin complex in the transition from colorectal adenoma to carcinoma. Anticancer Res 17 3C (1997) 2241-2247
134. Hiscox S., and Jiang W.G. Expression of E-cadherin, alpha, beta and gamma-catenin in human colorectal cancer. Anticancer Res 17 2B (1997) 1349-1354
135. Kitagawa T., et al. Co-expression of E-cadherin and alpha-catenin molecules in colorectal cancer. Surg Today 29 6 (1999) 511-518
136. Mikami T., et al. Decreased expression of CD44, alpha-catenin, and deleted colon carcinoma and altered expression of beta-catenin in ulcerative colitis-associated dysplasia and carcinoma, as compared with sporadic colon neoplasms. Cancer 89 4 (2000) 733-740
137. Raftopoulos I., et al. Level of alpha-catenin expression in colorectal cancer correlates with invasiveness, metastatic potential, and survival. J Surg Oncol 68 2 (1998) 92-99
138. Valizadeh A., et al. Expression of E-cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120) in colorectal polyps. Am J Pathol 150 6 (1997) 1977-1984
139. van der Wurff A.A., et al. Patterns of alpha- and beta-catenin and E-cadherin expression in colorectal adenomas and carcinomas. J Pathol 182 3 (1997) 325-330
140. Aaltomaa S., et al. Reduced alpha- and beta-catenin expression predicts shortened survival in local prostate cancer. Anticancer Res 25 6C (2005) 4707-4712
141. Arenas M.I., et al. E-, N- and P-cadherin, and alpha-, beta- and gamma-catenin protein expression in normal, hyperplastic and carcinomatous human prostate. Histochem J 32 11 (2000) 659-667
142. Kallakury B.V., Sheehan C.E., and Ross J.S. Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum Pathol 32 8 (2001) 849-855
143. Kallakury B.V., et al. Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer 92 11 (2001) 2786-2795
144. Morita N., et al. E-cadherin and alpha-, beta- and gamma-catenin expression in prostate cancers: correlation with tumour invasion. Br J Cancer 79 11-12 (1999) 1879-1883
145. Richmond P.J., et al. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 57 15 (1997) 3189-3193
146. Umbas R., et al. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer 74 4 (1997) 374-377
147. van Oort I.M., et al. The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120 (ctn) in prostate cancer specific survival: A long-term follow-up study. Prostate 67 (2007) 1432-1438
148. Bohm J., et al. Expression and prognostic value of alpha-, beta-, and gamma-catenins indifferentiated thyroid carcinoma. J Clin Endocrinol Metab 85 12 (2000) 4806-4811
149. Huang S.H., et al. Distribution of the cadherin-catenin complex in normal human thyroid epithelium and a thyroid carcinoma cell line. J Cell Biochem 70 3 (1998) 330-337
150. Kapran Y., et al. Immunohistochemical detection of E-cadherin, alpha- and beta-catenins in papillary thyroid carcinoma. J Endocrinol Invest 25 7 (2002) 578-585
151. Chow V., et al. A comparative study of the clinicopathological significance of E-cadherin and catenins (alpha, beta, gamma) expression in the surgical management of oral tongue carcinoma. J Cancer Res Clin Oncol 127 1 (2001) 59-63
152. Sakaki T., et al. Correlation of E-cadherin and alpha-catenin expression with differentiation of oral squamous cell carcinoma. J Osaka Dent Univ 33 2 (1999) 75-81
153. Tanaka N., et al. Expression of E-cadherin, alpha-catenin, and beta-catenin in the process of lymph node metastasis in oral squamous cell carcinoma. Br J Cancer 89 3 (2003) 557-563
154. Hidaka N., et al. Expression of E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin in bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma: an immunohistochemical study. Mod Pathol 11 11 (1998) 1039-1045
155. Lee Y.C., et al. The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated non-small cell lung cancers of 3cm or less in size. J Thorac Cardiovasc Surg 123 3 (2002) 502-507
156. Pirinen R.T., et al. Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol 54 5 (2001) 391-395
157. Toyoyama H., et al. The reduced expression of e-cadherin, alpha-catenin and gamma-catenin but not beta-catenin in human lung cancer. Oncol Rep 6 1 (1999) 81-85
158. Asayama Y., et al. The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-catenin and beta-catenin. Liver 22 1 (2002) 43-50
159. Endo K., et al. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol 31 5 (2000) 558-565
160. Ihara A., et al. Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology 23 6 (1996) 1441-1447
161. Kozyraki R., et al. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver. Gastroenterology 110 4 (1996) 1137-1149
162. Nuruki K., et al. E-cadherin but not N-cadherin expression is correlated with the intracellular distribution of catenins in human hepatocellular carcinomas. Oncol Rep 5 5 (1998) 1109-1114
163. Gunji N., et al. Pancreatic carcinoma: correlation between E-cadherin and alpha-catenin expression status and liver metastasis. Cancer 82 9 (1998) 1649-1656
164. Julkunen K., et al. alpha-, beta- and chi-catenin expression in human pancreatic cancer. Anticancer Res 23 6D (2003) 5043-5047
165. Karayiannakis A.J., et al. Expression patterns of alpha-, beta- and gamma-catenin in pancreatic cancer: correlation with E-cadherin expression, pathological features and prognosis. Anticancer Res 21 6A (2001) 4127-4134
166. Li Y.J., Meng Y.X., and Ji X.R. Relationship between expressions of E-cadherin and alpha-catenin and biological behaviors of human pancreatic cancer. Hepatobiliary Pancreat Dis Int 2 3 (2003) 471-477
167. Yonemasu H., et al. Phenotypical characteristics of undifferentiated carcinoma of the pancreas: a comparison with pancreatic ductal adenocarcinoma and relevance of E-cadherin, alpha catenin and beta catenin expression. Oncol Rep 8 4 (2001) 745-752
168. Joo Y.E., et al. Expression of E-cadherin, alpha- and beta-catenins in patients with pancreatic adenocarcinoma. Pancreatology 2 2 (2002) 129-137
169. Kozuki T., et al. Differences in p53 and cadherin-catenin complex expression between histological subtypes in diffusely infiltrating gastric carcinoma. Histopathology 41 1 (2002) 56-64
170. Ohene-Abuakwa Y., et al. Expression of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex correlates with the macroscopic appearance of early gastric cancer. J Pathol 192 4 (2000) 433-439
171. Song S.Y., et al. Abnormal expression of E-cadherin in early gastric carcinoma: its relationship with macroscopic growth patterns and catenin alpha and beta. J Clin Gastroenterol 38 3 (2004) 252-259
172. Yu J., et al. alpha-catenin expression is decreased in human gastric cancers and in the gastric mucosa of first degree relatives. Gut 46 5 (2000) 639-644
173. Zhou Y.N., et al. Alpha-catenin expression is decreased in patients with gastric carcinoma. World J Gastroenterol 11 22 (2005) 3468-3472
174. Kooy A.J., et al. Expression of E-cadherin, alpha- & beta-catenin, and CD44V6 and the subcellular localization of E-cadherin and CD44V6 in normal epidermis and basal cell carcinoma. Hum Pathol 30 11 (1999) 1328-1335
175. Papadavid E., et al. Abnormal immunoreactivity of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex in premalignant and malignant non-melanocytic skin tumours. J Pathol 196 2 (2002) 154-162
176. Zhang X.D., and Hersey P. Expression of catenins and p120cas in melanocytic nevi and cutaneous melanoma: deficient alpha-catenin expression is associated with melanoma progression. Pathology 31 3 (1999) 239-246
177. Clairotte A., et al. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol 125 1 (2006) 119-126
178. Koksal I.T., et al. Reduced E-cadherin and alpha-catenin expressions have no prognostic role in bladder carcinoma. Pathol Oncol Res 12 1 (2006) 13-19
179. Schrier B.P., et al. The predictive value of p53, p27 (kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur Urol 50 1 (2006) 76-82
180. Shimazui T., et al. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res 56 18 (1996) 4154-4158
181. Aaltomaa S., et al. The expression and prognostic value of alpha-, beta- and gamma-catenins in renal cell carcinoma. Anticancer Res 24 4 (2004) 2407-2413
182. Ashida K., et al. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology 27 4 (1998) 974-982
183. Li C.C., et al. Alterations of E-cadherin, alpha-catenin and beta-catenin expression in neuroendocrine tumors of the gastrointestinal tract. Virchows Arch 440 2 (2002) 145-154
184. Kashibuchi K., et al. The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. Eur Urol 49 5 (2006) 839-845 discussion 845
185. Ochiai A., et al. Frequent loss of alpha catenin expression in scirrhous carcinomas with scattered cell growth. Jpn J Cancer Res 85 3 (1994) 266-273
186. Spermon J.R., et al. alpha-Catenin expression pattern and DNA image-analysis cytometry have no additional value over primary histology in clinical stage I nonseminomatous testicular cancer. BJU Int 89 3 (2002) 278-284
187. Qian Z.R., et al. Role of E-cadherin, alpha-, beta-, and gamma-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. Mod Pathol 15 12 (2002) 1357-1365
188. Ramburan A., Hadley G.P., and Govender D. Expression of E-cadherin, cadherin-11, alpha-, beta- and gamma-catenins in nephroblastomas: relationship with clinicopathological parameters, prognostic factors and outcome. Pathology 38 1 (2006) 39-44
189. Mohan A., et al. Expression of motility-related protein MRP1/CD9, N-cadherin, E-cadherin, alpha-catenin and beta-catenin in retinoblastoma. Exp Eye Res 84 4 (2007) 781-789
190. Kumamoto H., and Ooya K. Expression of E-cadherin and alpha-catenin in epithelial odontogenic tumors: an immunohistochemical study. J Oral Pathol Med 28 4 (1999) 152-157
191. Yoshino I., et al. Expression status of E-cadherin and alpha-, beta-, and gamma-catenins in thymoma. Ann Thorac Surg 73 3 (2002) 933-937
192. Pan C.C., et al. Expression of E-cadherin and alpha- and beta-catenins in thymoma. J Pathol 184 2 (1998) 207-211
193. Shinoura N., et al. Expression of N-cadherin and alpha-catenin in astrocytomas and glioblastomas. Br J Cancer 72 3 (1995) 627-633
194. Tziortzioti V., et al. Analysis of beta-catenin mutations and alpha-, beta-, and gamma-catenin expression in normal and neoplastic human pituitary tissues. Endocr Pathol 12 2 (2001) 125-136
195. Shiozaki H., et al. Immunohistochemical detection of alpha-catenin expression in human cancers. Am J Pathol 144 4 (1994) 667-674
196. Naka T., et al. Immunohistochemical analysis of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin, and neural cell adhesion molecule (NCAM) in chordoma. J Clin Pathol 54 12 (2001) 945-950
197. Papadavid E., et al. The potential role of abnormal E-cadherin and alpha-, beta- and gamma-catenin immunoreactivity in the determination of the biological behaviour of keratoacanthoma. Br J Dermatol 145 4 (2001) 582-589
198. Sato H., et al. Expression of cadherins and their undercoat proteins (alpha-, beta-, and gamma-catenins and p120) and accumulation of beta-catenin with no gene mutations in synovial sarcoma. Virchows Arch 438 1 (2001) 23-30
199. Zhang Z.Y., et al. The expression of E-cadherin-catenin complex in adenoid cystic carcinoma of salivary glands. Chin J Dent Res 3 3 (2000) 36-39
200. Lou P., et al. Expression of E-cadherin/catenin complex in nasopharyngeal carcinoma: correlation with clinicopathological parameters. Oncol Rep 6 5 (1999) 1065-1071
201. Shieh Y.S., et al. Cadherin and catenin expression in mucoepidermoid carcinoma: correlation with histopathologic grade, clinical stage, and patient outcome. J Oral Pathol Med 32 5 (2003) 297-304
202. Shibuya Y., et al. Ultrastructural localization of E-cadherin and alpha-/beta-catenin in adenoid cystic carcinoma. Histopathology 35 5 (1999) 423-431
203. Mikami T., et al. Significant correlations of E-cadherin, catenin, and CD44 variant form expression with carcinoma cell differentiation and prognosis of extrahepatic bile duct carcinomas. Am J Clin Pathol 116 3 (2001) 369-376
204. San Miguel Fraile P., et al. Expresion of E-cadherin and catenins in urothelial carcinomas. Actas Urol Esp 31 4 (2007) 355-360